Search the database for deliberate release of GM medicinal products
Displaying 1 - 5 of 5
EU record number | Title | Company / Sponsor | Treated organism | Genetic modification |
---|---|---|---|---|
Only notified under the "contained use" procedure. Dossier submitted on 22/03/2016. | Phase I study to evaluate the safety and immunogenicity of a bivalent recombinant vaccine against human cytomegalovirus (HCMV). | Hookipa Biotech AG | Humans | Two replication-deficient lymphocytic choriomeningitidis virus (rLCMV) vectors, one expressing a truncated gBprotein of HCMV and one expressing the pp65 protein of the human CMV |
B/BE/12/BVW2 | Clinical trial evaluating the safety and efficacy of intracoronary administration of MYDICAR (AAV1/SERCA2a) in subjects with heart failure | Celladon | Humans | Human SERCA2a:CA++ pump involved in the regulation of heart contraction/relaxation cycle |
Only notified under the "contained use" procedure. Dossier submitted on 05/07/2005. | A multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of Biobypass (ADGVVEGF121.10NH) delivered by NOGATM-guided/MYOSTARTM catheter in "no option" patients with class II-IV stable angina | GenVec, Inc. | Humans | human VEGF121 |
Only notified under the "contained use" procedure. Dossier submitted on 10/06/2003. | A phase 1 randomized, placebo-controlled, double-blind, dose escalation trial to evaluate the safety and immunogenicity of tgAAC09, a gag-PR-DRT AAV HIV vaccine | International AIDS Vaccine Initiative (IAVI) | Humans | genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1 |
Only notified under the "contained use" procedure. Dossier submitted on 09/06/1998. | A phase II, multi-center, open label, randomized study to evaluate biodistribution and transmission, effectiveness and safety of two treatment regimens of Ad5CMV-p53 administered by intra-tumoral injections in 40 evaluable patients with advanced squamous | Rhone-Poulenc Rorer | Humans | Wild-type p53 |